The brain is less equipped to clear these additional pathologies
For decades, scientists have studied dementia's most destructive proteins one at a time, even as patients carry all of them at once. Researchers at TGen have now built a model that lets multiple proteins coexist and interact in a living brain, revealing that the sequence in which they arrive shapes how much harm they do — a finding that reframes not only how we understand neurodegeneration, but why so many promising treatments have failed when they meet the full complexity of human disease.
- Most dementia patients carry amyloid, tau, and alpha-synuclein simultaneously, yet nearly all laboratory research has studied these proteins in isolation — a mismatch that may explain decades of failed drug trials.
- A new TGen mouse model shows that when alpha-synuclein and tau arrive after amyloid plaques are already established, they amplify damage dramatically, producing more toxic protein forms and triggering hyperactivity and anxiety far beyond what amyloid alone causes.
- Tau pathology alone was found to ignite inflammation in white matter — the brain's connective wiring — a region clinicians rarely monitor, suggesting that current diagnostics may be systematically overlooking a critical front of the disease.
- Researchers now plan to run newly approved Alzheimer's drugs through this multi-protein model, testing whether therapies that succeed in simplified systems can survive contact with the biological complexity they will actually face in patients.
Most people who develop dementia carry more than one problem in their brain. Amyloid plaques, tau tangles, and alpha-synuclein — the protein linked to Parkinson's and Lewy body dementia — frequently appear together, yet science has largely studied them apart. That gap between laboratory simplicity and clinical reality has made it extraordinarily difficult to design treatments that hold up in the real world.
Researchers at TGen, part of City of Hope, set out to close that gap by engineering a mouse model capable of expressing multiple dementia proteins in different combinations and sequences. Led by John Fryer and first-authored by Benjamin Rabichow, the study was published in Alzheimer's & Dementia. Its central finding is that timing matters: the order in which these proteins appear in the brain profoundly shapes how destructive they become.
When alpha-synuclein and tau were introduced into mouse brains after amyloid plaques had already formed, the results were striking. The proteins didn't simply coexist — they amplified one another's damage, producing higher concentrations of toxic, misfolded forms and driving behavioral changes, including hyperactivity and anxiety, that were more severe than those caused by amyloid alone. One hypothesis is that amyloid overwhelms the cellular machinery responsible for clearing damaged proteins, leaving the brain ill-equipped to manage whatever arrives next.
When the same proteins were introduced before amyloid plaques developed, pathology still accumulated and behavior still changed — but more slowly and with less severity, suggesting that amyloid's presence fundamentally alters the brain's capacity to cope.
A separate finding added another layer of complexity: tau pathology alone provoked a strong inflammatory response in white matter, the brain's connective wiring between regions. Because clinicians typically focus their diagnostic attention on gray matter, where neurons cluster, this inflammation may be going undetected in patients.
The team's next step is to run newly approved Alzheimer's drugs through this mixed-pathology model — testing whether therapies that succeed in simplified systems can hold their own against the full, tangled reality of human dementia. The answer could help explain why so many drugs that looked promising in the lab have struggled to help real patients.
Most people who develop dementia don't have just one problem in their brain. They have several. Amyloid plaques accumulate alongside tau tangles. Alpha-synuclein shows up uninvited. These proteins tangle together in ways that scientists are only beginning to understand, and that gap in knowledge has made it nearly impossible to design treatments that work in the real world, where patients almost never have a single, clean pathology.
Researchers at TGen, part of City of Hope, have built a new tool to close that gap: a mouse model that can express multiple dementia proteins at once, in different combinations and sequences. The work, led by John Fryer and first-authored by Benjamin Rabichow, was published in Alzheimer's & Dementia: The Journal of the Alzheimer's Association. What they found suggests that the order in which these proteins appear in the brain matters enormously—and that the way they interact might hold clues to why some treatments work and others don't.
Alzheimer's disease, the most common form of dementia, is classically defined by two hallmarks: amyloid plaques and tau tangles. But in living patients, the picture is messier. Alpha-synuclein, the protein that defines Parkinson's disease and Lewy body dementia, frequently appears alongside these Alzheimer's markers. Some patients have all three. Until now, most laboratory studies have looked at these proteins in isolation, which means researchers have been studying a disease that doesn't actually exist in patients.
Rabichow and his team designed a viral delivery system that allowed them to introduce alpha-synuclein and tau into mouse brains at different timepoints—before amyloid plaques formed, and after. The results were striking. When alpha-synuclein and tau appeared after the amyloid was already present, they didn't just coexist peacefully. They amplified the damage. The mice developed higher levels of the toxic, misfolded versions of these proteins. Their behavior changed too: they became hyperactive and anxious, symptoms that were more pronounced than in mice with amyloid alone.
But when the researchers introduced alpha-synuclein and tau before the amyloid plaques formed, something different happened. The pathological proteins still accumulated robustly. The mice still developed behavioral changes. But the timeline was slower, and the severity was milder. This suggests that amyloid doesn't just add to the problem—it changes how the brain handles other proteins. One hypothesis is that amyloid overloads the cellular machinery responsible for clearing damaged proteins, leaving the brain less equipped to manage additional pathologies when they arrive.
There was another surprise. Tau pathology alone, independent of amyloid or alpha-synuclein, triggered a strong inflammatory response in non-neuronal cells within white matter tracts—the brain's wiring that connects different regions. This finding is significant because clinicians typically look for amyloid and tau in the gray matter where neurons cluster, not in the white matter where they communicate. It suggests that current diagnostic approaches might be missing important damage.
Fryer and his team are now planning to test newly approved Alzheimer's drugs on this mixed-pathology model. The goal is to see how these treatments perform in a system that actually resembles what happens inside a patient's brain. For decades, drug development has relied on models that are too simple. This work offers a way to test whether a therapy that works in isolation can handle the complexity of real disease. That distinction could mean the difference between a drug that looks promising in the lab and one that actually helps people.
Notable Quotes
The reality is that's often the case for many patients—they have all three proteins in the same system— Benjamin Rabichow, first author of the study
We want to see how these therapies react in more of a real-world situation with the pathologies that patients actually have— John Fryer, senior author and director of TGen's Center for Accelerated Nanotherapeutics
The Hearth Conversation Another angle on the story
Why does the order matter? If all three proteins end up in the brain anyway, why does it matter which one gets there first?
Because the brain has a limited capacity to handle damage. When amyloid is already there, it's like the cleanup crew is already overwhelmed. When tau and alpha-synuclein show up after that, the brain can't manage them as well. The proteins accumulate faster and cause more harm.
So amyloid is the worst offender?
Not necessarily the worst—just the one that seems to set the stage. It's more about the sequence. If tau and alpha-synuclein arrive first, the brain handles them differently. The damage is still there, but it develops more slowly.
What does this mean for someone who's already been diagnosed with Alzheimer's?
It means the drugs being developed now need to work in a brain that's already dealing with multiple problems at once. Testing them on a mouse with just amyloid plaques tells you almost nothing about whether they'll help a real patient.
And the white matter finding—why is that important?
Because doctors aren't looking there. They scan for amyloid and tau in the main body of the brain, but tau is also causing inflammation in the wiring that connects everything. You could be missing half the damage if you're not checking those connections.
So the next step is to see if the new drugs actually work in this more realistic model?
Exactly. This mouse model is finally a mirror of what's actually happening in patients. That's where real answers come from.